TNFRSF11B and plasma cell myeloma: The receptor activator of nuclear factor κB ligand (RANKL) (Tnfsf11) to osteoprotegerin (OPG) (Tnfrsf11b) ratio was increased in osteoblasts isolated from myeloma-bearing mice as compared to control; however, treatment of myeloma-bearing mice with LDN had no effect on the RANKL to OPG ratio (Fig. 4e), suggesting that the reduced osteoclast burden was not due to RANKL/OPG-mediated changes.